Ramsay Health Care (ASX:RHC) Earnings And Dividend Rise, Is It Now Slightly Overvalued?

Ramsay Health Care earnings jump and dividend update

Ramsay Health Care (ASX:RHC) has drawn fresh investor attention after reporting higher full year sales, revenue and net income for the year to June 30, 2026, alongside an increased fully franked dividend.

Over the past year, Ramsay Health Care's share price has gained momentum, with a 30 day share price return of 17.98% and a 90 day return of 42.79%. The 1 year total shareholder return of 58.31% sits against a more modest 3 year total shareholder return of 12.91% and a 5 year total shareholder return that is down 16.67%. This suggests that recent earnings and dividend announcements, plus board changes in late August, have shifted investor sentiment more positively than in prior years.

Extend your research beyond Ramsay Health Care by scanning a curated 8 dividend fortresses that could appeal if rising income streams and recent payout moves are on your radar.

Ramsay Health Care now sits between a strong earnings rebound and dividend uplift on one side, and a mixed multi year return record on the other. Do the numbers back the recent enthusiasm when you line price up against value?

Most Popular Narrative: 3% Overvalued

The most followed narrative currently pegs Ramsay Health Care's fair value at A$50.88, slightly below the last close of A$52.29. This frames the current optimism as relatively full rather than cheap.

The multiyear transformation program, focused on operational efficiency, digital transformation, and "One Ramsay" scale advantages (e.g., centralized procurement, standardization, enhanced theater utilization), is beginning to show results and is expected to drive further improvements in net margins and EBIT in FY '26 and beyond.

Read the complete narrative. Read the complete narrative.

This narrative is built around potential revenue lift and margin rebuild. The fair value hinges on measured growth, higher profitability, and a future earnings multiple that assumes investors stay patient with Ramsay Health Care's overhaul.

Result: Fair Value of A$50.88 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to weigh sector wide wage pressure and underperforming UK and European assets, which could limit margin progress and strain Ramsay Health Care's earnings story.

Find out about the key risks to this Ramsay Health Care narrative.

Another View: Ramsay Health Care through the SWS DCF lens

While the analyst narrative suggests Ramsay Health Care looks about 3% overvalued at A$52.29, the SWS DCF model points the other way. It puts fair value at A$54.05, which is slightly higher than today’s price. Which set of assumptions do you trust more for the long haul?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ramsay Health Care for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 10 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between Ramsay Health Care's recent momentum and its mixed longer term record, now is a good time to review the data yourself and decide how the risk and reward balance looks to you by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Ramsay Health Care?

If Ramsay Health Care has sharpened your focus, do not stop there. Cast the net wider now so you do not miss other compelling opportunities on your radar.

• Target resilience by checking companies with strong balance sheets and fundamentals using this focused list of solid balance sheet and fundamentals (21 results).
• Spot potential value by scanning a curated set of quality stocks that currently look attractively priced with the 10 high quality undervalued stocks.
• Strengthen income potential by reviewing companies that combine higher yields with robust profiles through the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com